EKF Establishes MDx Subsidiary, Buys Cancer Dx Company 360 Genomics | GenomeWeb

NEW YORK (GenomeWeb News) – UK-based point of care diagnostics firm EKF Diagnostics Holdings today announced it has formed a new firm to focus on molecular and companion diagnostics.

To support the creation of the new subsidiary called EKF Molecular Diagnostics, EKF also said that it has acquired cancer diagnostics company 360 Genomics for up to £9.6 million ($14.5 million).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.